Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients

详细信息    查看全文

• 作者：Gang Zhou (1) zhougang2007.hu@163.com
  Lizhi Niu (1) Lizhi2009@163.com
  David Chiu (1) chiudw@163.com
  Lihua He (1) helihua2009@126.com
  Kecheng Xu (1) xukc@vip.163.com
• 关键词：Chemotherapy – Cryosurgery – Pancreatic cancer – Tumor markers
• 刊名：Biotechnology Letters
• 出版年：2012
• 出版时间：July 2012
• 年：2012
• 卷：34
• 期：7
• 页码：1235-1241
• 全文大小：391.3 KB
• 参考文献：1. Banfi G, Bravi S, Ardemagni A (2000) Quantitative analysis of CA125 cytosolic contest in patients with pancreatic cancer. Int J Biol Markers 18:284
  2. Carpelan M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54:385–387
  3. Eickhoff A, Martin W, Hartmann D (2006) A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma. Br J Cancer 94:1572–1574
  4. Gage AA, Baust JG (2007) Cryosurgery for tumors. J Am Coll Surg 205:342–356
  5. Giannini E, Borro P, Botta F (2001) Cholestasis is the main determinant of abnormal CA199 levels in patients with pancreatic cancer. Int J Biol Markers 15:126–129
  6. Giraudo E, Primo L, Audero E (1998) Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor and of its coreceptor neuropilin-1 human vascular endothelial cells. J Biol Chem 34:22128–22135
  7. Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, Katsuramaki T (2007) Current status of surgery for PC. Dig Surg 24:137–141
  8. Jiang JT, Wu CP, Deng HF (2004) Serum Level of CEA, CA242 and CA199 in pancreatic cancer. World J Gastroenterol 10:1675–1679
  9. Kang CM, Kim JY, Choi GH (2007) The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140:31–35
  10. Kovach SJ, Hendrickson RJ, Cappadona CR (2002) Cryoablation of unresectable PC. Surgery 131:463–465
  11. Michalski CW, Weitz J, Buchler MW (2007) Surgery insight: surgical management of PC. Nat Clin Pract Oncol 24:526–535
  12. Mouraviev V, Polascik TJ (2006) Update on cryosurgery for prostate cancer. Curr Opin Urol 16:152–156
  13. Okusaka T, Ishii H, Funakoshi A, Ueno H, Furuse J, Sumii T (2006) A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. Jpn J Clin Oncol 36:557–563
  14. Park BB, Park JO (2007) A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 60:489–494
  15. Schlieman MG, Bold RJ (2003) Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138:951–956
  16. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler M (2008) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586–589
  17. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V (2006) Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable PC. JOP 7:349–360
  18. Xu KC, Niu LZ (2003) Sequential treatment of transarterial chemoembolization (TACE)-percutaneous cryosurgery for unresectable primary liver cancer. World J Gastroenterol 9:2688–2689
  19. Xu KC, Niu LZ (2008) Cryosurgery with combination of 125iodine seed implantation for the treatment of locally advanced PC. J Dig Dis 9:234–237
  20. Xu KC, Niu LZ, He WB (2003) Percutaneous cryosurgery in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol 59:2686–2689
  21. Xu KC, Niu LZ, Hu YZ (2008) A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J Gastroenterol 14:1603–1611
• 作者单位：1. Department of Oncology, The GIBH Affiliated Fuda Hospital, Chinese Academy of Sciences, 91 Jude Zhong Road, Chigang, Guangzhou, 510305 China
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Microbiology
  Biotechnology
  Applied Microbiology
  Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-6776

文摘

The presence of serum tumor markers, carbohydrate antigen 242 (CA242), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), tumor-supplied group of factors (TSGF) and tumor necrosis factor-α (TNF-α), is closely associated with invasion and metastasis of many malignancies. The expression of these markers were measured in serum taken from 37 pancreatic cancer patients prior to treatment. Levels of CA242, CA199, CA125, CEA and TNF-α expression correlated with tumor size, clinical stage, tumor differentiation, lymph node and liver metastasis (P < 0.05). One month after cryosurgery, serum levels of these markers were significantly reduced compared with levels prior to cryosurgery (P < 0.05), whereas there was no significant difference was found between serum levels before and after chemotherapy (P > 0.05). Thus, cryosurgery is more effective than chemotherapy for decreasing CA242, CA199, CA125, CEA, TSGF and TNF-α serum levels in these patients.